The GLP-1 Revolution Has Three Contenders

The weight loss pharmaceutical landscape has transformed dramatically since the arrival of GLP-1 receptor agonists. What began as a two-horse race between Mounjaro (tirzepatide) and Ozempic (semaglutide) has become a three-way competition with the FDA approval of Foundayo (orfiglutide) in late 2025. For millions of Americans considering medical weight management, understanding the differences between these medications has never been more important.

How Each Medication Works

All three drugs belong to the GLP-1 receptor agonist class, but they differ in their mechanisms of action. Ozempic targets the GLP-1 receptor alone, mimicking the incretin hormone that regulates blood sugar and appetite. Mounjaro goes a step further by targeting both GLP-1 and GIP receptors, a dual-agonist approach that Eli Lilly argues provides superior metabolic benefits.

Foundayo, developed by AstraZeneca, represents the newest approach. It targets GLP-1, GIP, and glucagon receptors simultaneously, making it the first triple-agonist approved for weight management. Early clinical data suggests this broader mechanism may offer advantages in both weight loss and metabolic health markers.

Effectiveness Comparison

Clinical trial data paints a compelling picture across all three medications:

However, real-world results often differ from clinical trials. Patient adherence, lifestyle factors, and individual biology all play significant roles. Endocrinologists emphasize that the best medication is the one a patient can consistently take and tolerate.

Side Effects and Tolerability

Gastrointestinal side effects remain the most common complaint across all three drugs. Nausea, vomiting, diarrhea, and constipation affect between 20-40% of patients during the dose-titration phase. Foundayo initially reported slightly higher GI side effect rates in early trials, though the approved slow-titration protocol has helped mitigate this concern.

The key to minimizing side effects with any GLP-1 agonist is proper dose titration. Rushing the process almost always leads to poor tolerability. — Dr. Sarah Chen, Endocrinologist at Cleveland Clinic

More serious concerns include potential thyroid C-cell tumor risk, which carries a boxed warning on all three medications. Pancreatitis and gallbladder problems have also been reported, though rates remain relatively low across all products.

Cost and Insurance Coverage

Pricing remains a significant barrier for many patients. Without insurance, monthly costs are substantial for all three options. Ozempic lists at approximately $900 per month, Mounjaro at around $1,050, and Foundayo entered the market at approximately $980, strategically positioned between its competitors.

Insurance coverage varies dramatically. Medicare began covering these medications for obesity in January 2026 following the passage of the Treat and Reduce Obesity Act. Private insurers have been more inconsistent, with some plans covering all three options and others restricting coverage to specific diagnoses.

Which One Is Right for You?

The choice between these medications should be made in consultation with a healthcare provider who understands your complete medical history. Factors to consider include your specific health conditions, insurance coverage, tolerance for injections, and personal health goals.

For patients with Type 2 diabetes, Ozempic and Mounjaro both carry diabetes indications and may be easier to obtain insurance coverage for. Foundayo is currently approved only for chronic weight management in adults with a BMI of 30 or higher, though diabetes trials are underway.

As the GLP-1 market continues to evolve, patients have more effective options than ever before. The competition between these three pharmaceutical giants is driving innovation and, gradually, improving access to treatments that can meaningfully impact metabolic health.